Keira Bell’s lawsuit against the Tavistock and Portman NHS Foundation Trust ended in legal defeat but political victory. She won at the High Court in December 2020, lost on appeal in September 2021, and was refused permission to appeal to the Supreme Court in May 2022. Even so, the case helped trigger the closure of the Tavistock’s gender identity clinic for children and an indefinite NHS ban on prescribing puberty blockers to under-18s for gender dysphoria outside of clinical trials.
Who Keira Bell Is and Why She Sued
Bell was referred to the Tavistock’s Gender Identity Development Service (GIDS) at age 15 and diagnosed with gender dysphoria. She was placed on puberty-suppressing drugs at 16, started testosterone at 17, and had a double mastectomy at 20.1Persuasion. Keira Bell: My Story
She began detransitioning at 22. Bell came to believe her dysphoria was a symptom of depression, anxiety, and trauma rather than a condition in its own right, and she has described lasting physical consequences including possible infertility, a permanently deepened voice, facial hair, and nerve damage from surgery.1Persuasion. Keira Bell: My Story That experience drove the lawsuit.
The 2020 High Court Ruling
Bell and an anonymous co-claimant, “Mrs A,” brought judicial review proceedings against the Tavistock Trust. The case, Bell v Tavistock [2020] EWHC 3274 (Admin), was heard by Dame Victoria Sharp, Lord Justice Lewis, and Mrs Justice Lieven.2UK Judiciary. Bell v Tavistock Judgment
The core question was whether children could be “Gillick competent” to consent to puberty blockers. Under the Gillick standard, a child under 16 can consent to treatment if they have sufficient understanding to appreciate what is involved. The claimants said the complexity and unknown long-term effects of puberty blockers put the treatment beyond most children’s grasp.
On December 1, 2020, the court agreed. The judges concluded it was “highly unlikely” that a child aged 13 or under could ever be Gillick competent to consent to puberty blockers, and doubted that 14- and 15-year-olds could meet the threshold either. They described the drugs as a significant, potentially life-altering intervention with unknown long-term effects, functioning not as a neutral pause but as “a first step in a pathway of physical treatment.”2UK Judiciary. Bell v Tavistock Judgment In practice, the ruling required clinicians to seek court authorization before prescribing puberty blockers to under-16s.
NHS England responded within days. The Tavistock was barred from accepting new referrals for the affected treatments, and access to puberty blockers and cross-sex hormones froze for patients under 16.3openDemocracy. Mermaids Report Tavistock Keira Bell Mental Health Trans Hormones
The 2021 Court of Appeal Reversal
The Tavistock appealed. On September 17, 2021, the Court of Appeal allowed the appeal and set the High Court’s ruling aside in full. The panel comprised the Lord Chief Justice (Lord Burnett of Maldon), the Master of the Rolls (Sir Geoffrey Vos), and Lady Justice King.4UK Judiciary. Bell v Tavistock Court of Appeal Judgment
The appellate court found three principal errors. First, the High Court had made findings of fact on contested clinical questions, such as whether puberty blockers were experimental or whether most patients progressed to cross-sex hormones, when judicial review is not the venue for resolving that kind of evidence.4UK Judiciary. Bell v Tavistock Court of Appeal Judgment Second, issuing age-based generalizations about consent placed an “improper restriction” on the Gillick test, which treats competence as a clinical judgment for doctors to make on an individual basis rather than a checklist for judges to write. Third, requiring blanket court authorization would cause “inevitable delay” and effectively deny treatment in many cases.5The Transparency Project. Bell v Tavistock Court of Appeal Judgment: An Explainer
The judges added that it was not the courts’ role to decide whether a particular medical treatment is wise. Those questions belonged to the NHS, medical regulators, and Parliament. Since the lower court had found no illegality in the Trust’s policies, the appellate court said, it should have dismissed the claim.4UK Judiciary. Bell v Tavistock Court of Appeal Judgment
Supreme Court Refusal
Bell asked the UK Supreme Court for permission to appeal. On May 5, 2022, the court refused, finding the case raised “no arguable point of law.”6Irish Legal. England Supreme Court Refuses Application for Appeal in Puberty Blockers Case That refusal ended the litigation and left the Court of Appeal’s reversal as the final word.
What Changed Anyway
Bell lost the case but the policy landscape moved her way. NHS England had already commissioned an independent review of youth gender services under pediatrician Hilary Cass. Its 2022 interim findings described GIDS as “unsustainable” and called for a different model of care.7Tortoise Media. Tavistock: Britain’s Biggest Gender Identity Clinic Has Closed NHS England announced GIDS’s closure on July 28, 2022, and the clinic shut for good on March 31, 2024.8The Guardian. Why the Tavistock Gender Identity Clinic Was Forced to Shut and What Happens Next
The replacement is a network of regional hubs that lead with psychological and psychotherapeutic support rather than medication, with sites in London, north-west England, and the Bristol area and plans to expand to as many as eight clinics.8The Guardian. Why the Tavistock Gender Identity Clinic Was Forced to Shut and What Happens Next The final Cass Review in 2024 concluded the Tavistock had been “implementing ‘innovative’ changes in care without a well-considered evidence base.”9NHS England. Implementing the Cass Review Recommendations
In March 2024, NHS England stopped prescribing puberty blockers for gender dysphoria, citing insufficient evidence of safety and effectiveness.7Tortoise Media. Tavistock: Britain’s Biggest Gender Identity Clinic Has Closed Temporary restrictions on private prescribing followed in May 2024, and an indefinite ban took effect on January 1, 2025 under the Medicines (Gonadotrophin-Releasing Hormone Analogues) (Restrictions on Private Sales and Supplies) Order 2024, which prohibits the sale and supply of puberty blockers for gender dysphoria in under-18s and is scheduled for review in 2027.10UK Government. Ban on Puberty Blockers to Be Made Indefinite on Experts Advice The Commission on Human Medicines advised the indefinite restriction on the basis that allowing use of these drugs for this purpose posed an “unacceptable safety risk.”11BMJ. Puberty Blockers Ban Made Indefinite The ban applies to gender dysphoria treatment; puberty blockers remain available for other clinical uses.
Bell’s Follow-On Legal Actions
Bell has not left the courts. In January 2025 she was one of three claimants represented by Sinclairs Law who threatened judicial review against Health Secretary Wes Streeting, demanding a ban on cross-sex hormones for under-18s and arguing that the logic behind the puberty-blocker restrictions applied equally to hormones.12BBC. Keira Bell Campaigns for Ban on Cross-Sex Hormones for Under-18s The pre-action letter became a formal judicial review application, still active as of mid-2026.13The Times. Failure to Ban Cross-Sex Hormone Treatment Must Be Reviewed
In December 2025, Bell joined a second challenge with the Bayswater Support Group and psychotherapist James Esses targeting the NHS-funded “Pathways” clinical trial of puberty blockers, arguing that the trial “fails to safeguard the rights, safety and wellbeing” of vulnerable children.14The Guardian. Campaigners in Legal Effort to Suspend Trial of Puberty Blockers in England The formal judicial review claim was filed on February 6, 2026. Shortly afterward the medicines regulator placed the trial on hold, an initial hearing was held on March 6, 2026, and a main hearing was scheduled for July 2026.15Sex Matters. Timeline of Puberty Blockers and Cross-Sex Hormones for Children Both cases remain ongoing.